Trading on the Canadian Stock Exchange under the ticker symbol CMND is Clearmind Medicine, a drug development company working on treatments for binge behavior and mental health, including alcohol use disorder, binge eating, and depression.
While the company is working through the usual checklist common to early-stage preclinical biotech firms, they do have something that immediately seems to set them apart: MEAI (5-methoxy-2-aminoindane or 5-MeO-AI), a compound that Clearmind owns the rights to, and it has some serious potential for stopping addictive behavior.
Dr. Adi Zuloff-Shani, CEO, and Mark Haden, VP Business Development joined Microdose at our recent Psychedelic Capital event. From Dr. Zuloff-Shani:
We offer an appealing approach to healing alcoholism. MEAI delivers an altered and sociable feeling, while also creating a that’s enough switch in the brain, preventing overuse. We believe that MEAI breaks the vicious binge-drinking cycle at the decision point to drink more alcohol by potentially inverting neural pathways such as 5hT2AA receptors.
According to Clearmind, MEAI could break the vicious binge-drinking cycle by potentially “innervating neural pathways such as 5-HT1A, which leads to decreased impulsivity”. With dozens of companies racing to drive classic psychedelics through clinical trials, or spending years and untold millions developing next-generation versions of these well-known molecules, Clearmind could have its own market with MEAI (if its promise comes to fruition).
We are already in the process of preparing a pre-IND meeting and submissions to the FDA for the 1st human study, projected to be initiated at the end of the year.
And controlling craving behavior may have a wider range of applications beyond just shrinking. We’ve launched another study to research the effect of MEAI on binge eating and other metabolic disorders.
Click here for more information on the science and IP, and here’s a deeper look from Mark Haden, Clearmind’s VP Business Development, describing the MEAI treatment experience:
Also, see the company’s recent press release on results from their CMND-100 trial.
Clearmind Medicine Announces Positive Results on CMND-100 trials
Clearmind Medicine Inc.
Two pre-clinical trials based on MEAI exhibited a significant suppressive effect on alcohol consumption in mice
TORONTO, March 17, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND, OTC Pink: CMNDF, FSE: CWY0) (“Clearmind” or the “Company”) today announced promising results from two pre-clinical trials which tested suppression of alcohol consumption in mice using its novel psychedelic-based therapeutic CMND-100, whose active pharmaceutical ingredient is MEAI.
The first trial examined the effect of CMND-100 in several doses as a monotherapy. The second, done in collaboration with SciSparc Ltd. (NASDAQ: SPRC), examined the synergetic effect of combining lower concentrations of CMND-100 with SciSparc’s CannAmide™ (proprietary formulation of Palmitoylethanolamide or PEA) .
“We are excited to reveal that our proprietary CMND-100 showed very positive results that suggest strong potential for treating alcohol use disorder,” said Dr. Adi Zuloff-Shani, PhD, the CEO of Clearmind, which focuses on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems.
As part of the trials, the mice were provided with a 20% alcohol solution for 24 hours, three times a week for 7 weeks – and treated with MEAI daily during the last two weeks. The mice had free access to water to test their alcohol preference over water. Alcohol consumption was measured by weighing the alcohol bottles before and after. CMND-100 at doses of 40 mg/kg and higher demonstrated significant suppressive effect on alcohol consumption, reducing the alcohol consumed significantly lower than untreated controls (p<0.01).
The second trial aimed to test the hypothesis that sub-effective doses of CMND-100 in combination with CannAmide will further attenuate alcohol consumption (PEA is known as a safe neuro-potentiator). Results showed a significant reduction in alcohol consumption at the lower sub-effective MEAI dose when combined with CannAmide.
“CMND-100 showed very positive results both in our own target dose and in lower doses combined with SciSparc’s CannAmide™,” Zuloff-Shani said. “These results are a proof of concept for our goal of developing innovative, effective, and safe psychedelic treatments that could revolutionize the mental health market
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The company’s intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol “CMND”, the Frankfurt Stock Exchange under the symbol “CWYO” and on the OTC pink under the symbol “CMNDF”.
For further information, please contact:
Investor Relations
Telephone: (604) 260-1566
General Inquiries
www.Clearmindmedicine.com